title: Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey.
abstract: Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23%. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.
authors.affiliation: Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama City, Saitama, Japan. ycanda-tky@umin.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: Y
authors.initials: Y
authors.lastname: Omuro
authors.forename: E
authors.initials: E
authors.lastname: Baba
authors.forename: K
authors.initials: K
authors.lastname: Oshima
authors.forename: K
authors.initials: K
authors.lastname: Nagafuji
authors.forename: Y
authors.initials: Y
authors.lastname: Heike
authors.forename: Y
authors.initials: Y
authors.lastname: Takaue
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: M
authors.initials: M
authors.lastname: Harada
mesh_terms: D000328:Adult; D000368:Aged; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D002272:Carcinoembryonic Antigen